Format

Send to

Choose Destination
Diabetes Care. 2011 Nov;34(11):2474-6. doi: 10.2337/dc11-1099.

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials.

Author information

1
Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, Careggi Teaching Hospital, Florence, Italy.

Erratum in

  • Diabetes Care. 2014 Jan;37(1):312.

Abstract

OBJECTIVE:

Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far.

RESEARCH DESIGN AND METHODS:

A meta-analysis was performed including all randomized clinical trials with a duration of at least 24 weeks, enrolling patients with type 2 diabetes, comparing DPP-4 inhibitors with placebo or active drugs.

RESULTS:

Twenty-eight trials enrolling 11,880 and 9,175 patients for DPP-4 inhibitors and comparators, respectively, were included, reporting 63 fractures. DPP-4 inhibitors, compared with placebo or other treatments, were associated with a reduced risk of fractures (Mantel-Haenszel odds ratio [MH-OR] 0.60, 95% CI 0.37-0.99, P = 0.045), even after the exclusion of comparisons with thiazolidinediones or sulfonylureas (MH-OR 0.56, 0.33-0.93, P = 0.026).

CONCLUSIONS:

The present meta-analysis suggests that treatment with DPP-4 inhibitors could be associated with a reduced risk of bone fractures.

PMID:
22025784
PMCID:
PMC3198283
DOI:
10.2337/dc11-1099
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central Icon for PubMed Health
Loading ...
Support Center